

February 6, 2013

The Manager - Listing
Bangalore Stock Exchange Ltd.
Stock Exchange Tower
51, 1st Cross, J C Road
Bangalore 560 027

The Manager – Listing
Bombay Stock Exchange Limited
Corporate Relationship Department
P J Towers, Dalal Street
Fort, Mumbai 400 001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra - Kurla Complex
Mumbai – 400 051

Dear Sir(s),

Sub: Outcome of Board Meeting held on Wednesday, February 6, 2013

Ref: Scrip Code - Bgse: ASTRAZEN /BSE: 506820 / NSE: ASTRAZEN EQ

This is to inform you that at the Board Meeting of the Company held today i.e. February 6, 2013, the Board approved, inter alia, the appointment of Mr. Robert Ian Haxton as an Additional Director as well as Wholetime Director of the Company for a period of 2 years, with effect from February 6, 2013.

We would also like to inform you that the Company has in January 2013, experienced a further interruption in the production which is under the process of remediation.

Thanking you,

Yours faithfully,
for **AstraZeneca Pharma India Limited**


Pawan Singh
Vice President - Legal & Company Secretary

Financial results for the quarter and nine months ended 31 December 2012

Part I		Rs in lakhs (except for number of shares)					
Sl No.	Particulars	3 months ended 31/12/2012	3 months ended 30/09/2012	3 months ended 31/12/2011	9 months ended 31/12/2012	9 months ended 31/12/2011	Previous year ended 31/03/2012
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from operations						
	a) Net sales/ income from operations (net of excise duty)	10,491.39	9,922.82	15,348.33	29,540.29	43,958.99	53,127.97
	b) Other operating income	2.49	4.88	3.88	10.16	14.35	24.05
	Total income from operations (net)	10,493.88	9,927.70	15,352.21	29,550.45	43,973.34	53,152.02
2	Expenses						
	(a) Cost of materials consumed	947.74	1,379.29	1,349.33	3,042.88	5,742.23	7,151.68
	(b) Purchase of stock-in-trade	3,071.44	2,429.15	5,320.28	8,124.13	11,088.85	11,923.13
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	20.06	563.69	(1,941.87)	1,035.99	(3,426.54)	(1,210.38)
	(d) Employee benefits expense	3,965.48	3,859.01	3,523.09	11,164.04	10,400.15	16,191.24
	(e) Depreciation and amortisation expense	254.01	250.31	188.81	679.46	552.83	733.86
	(f) Other expenses	4,026.31	3,701.78	4,859.03	11,652.51	12,226.29	16,070.05
	Total expenses	12,285.04	12,183.23	13,298.67	35,699.01	36,583.81	50,859.58
3	Profit/ (loss) from operations before other income, finance costs and exceptional items (1-2)	(1,791.16)	(2,255.53)	2,053.54	(6,148.56)	7,389.53	2,292.44
4	Other income	21.63	173.92	146.44	979.08	431.63	633.04
5	Profit/ (loss) from ordinary activities before finance costs and exceptional items (3+4)	(1,769.53)	(2,081.61)	2,199.98	(5,169.48)	7,821.16	2,925.48
6	Finance costs	-	-	-	-	-	-
7	Profit/ (loss) from ordinary activities after finance costs but before exceptional items (5-6)	(1,769.53)	(2,081.61)	2,199.98	(5,169.48)	7,821.16	2,925.48
8	Exceptional items	-	-	-	-	-	-
9	Profit/ (loss) from ordinary activities before tax (7+8)	(1,769.53)	(2,081.61)	2,199.98	(5,169.48)	7,821.16	2,925.48
10	Tax expense	-	2,429.97	706.24	1,926.23	2,544.20	948.97
11	Net profit/(loss) from ordinary activities after tax (9-10)	(1,769.53)	(4,511.58)	1,493.74	(7,095.71)	5,276.96	1,976.51
12	Extraordinary Item	-	-	-	-	-	-
13	Net profit/(loss) for the period (11-12)	(1,769.53)	(4,511.58)	1,493.74	(7,095.71)	5,276.96	1,976.51
14	Paid-up equity share capital (Face value of Rs 2 per equity share)	500.00	500.00	500.00	500.00	500.00	500.00
15	Reserves excluding revaluation reserves as per the balance sheet of previous accounting year						18,428.52
16	Basic and diluted earnings (Rs) per share (not annualised)	(7.08)	(18.05)	5.97	(28.38)	21.11	7.91
	See accompanying notes to the financial results						
Part II							
A	Particulars of shareholding						
1	Public shareholding						
	- Number of shares	2,500,050	2,500,050	2,500,050	2,500,050	2,500,050	2,500,050
	- Percentage of shareholding	10.0002%	10.0002%	10.0002%	10.0002%	10.0002%	10.0002%
2	Promoters and promoter group shareholding						
	a) Pledged/Encumbered						
	- Number of shares	-	-	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of shares	22,499,950	22,499,950	22,499,950	22,499,950	22,499,950	22,499,950
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	89.9998%	89.9998%	89.9998%	89.9998%	89.9998%	89.9998%
B.	Particulars			3 months ended 31/12/2012			
	Investor complaints						
	Pending at the beginning of the quarter			Nil			
	Received during the quarter			8			
	Disposed of during the quarter			8			
	Remaining unresolved at the end of the quarter			Nil			

Notes:

- The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 06 February 2013.
- The Company's sole reportable business segment is - 'Healthcare'. The other segments are not material and are hence disclosed as 'Others'. Others comprise service income pertaining to clinical trials and co-promotion activities.
- Other income for the nine months period ended 31 December 2012 includes an amount of Rs 693.49 lakhs towards compensation for 'Others'. Other acquired by National Highway Authority of India in the previous year.
- At the end of the previous financial year, the factory experienced interruptions to the supply of certain products. While several products have been returned to the market, the Company continues to pursue a remediation plan to address these interruptions. As a result of these interruptions, revenues and the financial results for the current quarter and nine months period ended 31 December 2012 are lower compared to the prior year. In January 2013, the factory experienced a further interruption in production which is under process of remediation.
- In view of the inadequacy of profit during the current period, the remuneration paid to the Managing Director up to 31 August 2012 (date of his resignation) and that paid/ payable to the Whole Time Director is subject to compliance with the requirements of Schedule XIII to the Companies Act, 1956
- Tax expense represents deferred tax assets amounting to Rs 2,429.97 lacs which have been charged to the profit and loss for the quarter ended 30 September 2012.
- The above statement of financial results have been reviewed by the statutory auditors. The statutory auditors have issued an unqualified review report. The review report has been filed with the stock exchange and is also available on the company's website.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

Ruby Lau
Whole Time Director

6/2/13.

Bangalore
Dated: 06 February 2013

AstraZeneca Pharma India Limited
Regd. Office : 'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

Segment wise revenue, results and capital employed

Sl.no.	Particulars	3 months ended 31/12/2012	3 months ended 30/09/2012	3 months ended 31/12/2011	9 months ended 31/12/2012	9 months ended 31/12/2011	Previous year ended 31/03/2012
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Segment revenue						
	(a) Healthcare	9,463.99	9,259.78	14,520.43	27,051.19	41,674.09	49,977.92
	(b) Others	1,029.89	667.92	831.78	2,499.26	2,299.25	3,174.10
	Total	10,493.88	9,927.70	15,352.21	29,550.45	43,973.34	53,152.02
	Less: Inter-segment revenue	-	-	-	-	-	-
	Net income from operations	10,493.88	9,927.70	15,352.21	29,550.45	43,973.34	53,152.02
2	Segment results						
	Profit/(loss) before tax and interest						
	(a) Healthcare	(2,003.34)	(2,306.31)	2,047.27	(6,387.90)	7,287.85	2,165.28
	(b) Others	212.18	50.78	6.27	239.34	101.68	127.16
	Total	(1,791.16)	(2,255.53)	2,053.54	(6,148.56)	7,389.53	2,292.44
	Add: Other income	21.63	173.92	146.44	979.08	431.63	633.04
	Less: Interest	-	-	-	-	-	-
	Total profit/(loss) before tax	(1,769.53)	(2,081.61)	2,199.98	(5,169.48)	7,821.16	2,925.48
3	Capital employed						
	(a) Healthcare	8,217.69	9,279.12	15,527.13	8,217.69	15,527.13	11,722.25
	(b) Others	184.81	454.42	562.23	184.81	562.23	817.67
	(c) Unallocated	3,430.31	3,868.80	7,156.55	3,430.31	7,156.55	6,388.60
	Total	11,832.81	13,602.34	23,245.91	11,832.81	23,245.91	18,928.52

Notes :

1 Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.


6/2/12.

BSR & Co.

(Registered)

Chartered Accountants

Maruthi Info-Tech Centre
11-12/1 Inner Ring Road
Koramangala
Bangalore 560 071 India

Telephone +91 80 3980 6000
Fax +91 80 3980 6999


Review report to the Board of Directors of AstraZeneca Pharma India Limited

We have reviewed the accompanying statement of unaudited financial results of AstraZeneca Pharma India Limited ("the Company") for the quarter and nine months ended 31 December 2012 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the Management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results for the quarter and nine months ended 31 December 2012, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement, including the manner in which it is to be disclosed, or that it contains any material misstatement.

for BSR & Co.
Chartered Accountants
Firm Registration Number: 101248W


Zubin Shukary
Partner
Membership Number: 48814

Place: Bangalore
Date: 6 February 2013